Skip to main content
SpringerLink
Log in

Tafluprost: a novel prostaglandin analog for treatment of glaucoma

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Objective

The objective of this review is to evaluate the safety and efficacy of tafluprost, a fluoroprostaglandin receptor analog, for reduction of intraocular pressure in open angle glaucoma and ocular hypertension.

Methods

A search of published literature was performed on the PubMed database using the search term “tafluprost.” The literature search identified 48 publications, including clinical and preclinical studies, from 2003 to 2011. From these ressults, articles available in the English language and in full text were selected and systematically reviewed by the authors.

Results

Recent studies have shown that tafluprost is an effective IOP-lowering medication. Evidence based medicine also reveals that tafluprost is safe and well-tolerated. Preservative-free tafluprost is as potent as the preserved formulation, but with fewer and milder ocular surface side effects.

Conclusion

Since its introduction in 2008, initial studies have demonstrated that preserved and preservative-free tafluprost formulations have proven efficacy and safety in the treatment of glaucoma and ocular hypertension. Larger studies with longer follow-up are needed to assess long-term safety, efficacy, and tolerability compared with other prostaglandin analogs used for treating glaucoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440.

    Article  Google Scholar 

  2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.

    PubMed  Google Scholar 

  3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713.

    PubMed  Google Scholar 

  4. Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol. 2004;15:102–106.

    Article  Google Scholar 

  5. Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin F2a derivatives with prostanoid FP-receptor agonistic activity as potent ocular hypotensive agents. Biol Pharm Bull. 2003;26:1691–1695.

    Article  PubMed  CAS  Google Scholar 

  6. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid receptor FP agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–776.

    Article  PubMed  CAS  Google Scholar 

  7. Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservativefree tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf). 2008;242:S14–S19.

    Google Scholar 

  8. Sutton A, Gilvarry A, Ropo A. A comparative placebocontrolled study of prostanoid fluoroprostaglandin receptor agonist tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther. 2007;23:359–365.

    Article  PubMed  CAS  Google Scholar 

  9. Sutton A, Gouws P, Ropo A. Tafluprost a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther. 2008;46:400–406.

    PubMed  CAS  Google Scholar 

  10. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf). 2008;242:S7–S13.

    Google Scholar 

  11. Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010;4:163–170.

    Article  PubMed  Google Scholar 

  12. Fukano Y, Kawazu K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos. 2009;37:1622–1634.

    Article  PubMed  CAS  Google Scholar 

  13. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501–515.

    Article  PubMed  CAS  Google Scholar 

  14. Kurashima H, Asai Y, Aihara M, Ishida N, Nakamura M, Araie M. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys. J Glaucoma. 2011. Epub ahead of print.

  15. Ota T, Murata H, Sugimoto E, et al. Prostaglandin analogues and mouse intraocular pressure: Effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24 hour variation. Invest Ophthalmol Vis Sci. 2005;46:2006–2011.

    Article  PubMed  Google Scholar 

  16. Ota T, Aihara M, Saeki T, et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol. 2007;91:673–676.

    Article  PubMed  Google Scholar 

  17. Akaishi T, Odani-Kawabada N, Ishida N, et al. Ocular hypotensive effects of anti-glaucoma agents in mice. J Ocul Pharmacol Ther. 2009;25:401–408.

    Article  PubMed  CAS  Google Scholar 

  18. Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Opin Ophthalmol. 2005;16:79–83.

    Article  PubMed  Google Scholar 

  19. Michelson G, Langhans MJ, Groh, MJ. Perfusion of the juxtapapillary retina and the neuroretinal rim area in primary open angle glaucoma. J Glaucoma. 1996;5:91–98.

    PubMed  CAS  Google Scholar 

  20. Yamazaki Y, Hayamizu F. Comparison of flow velocity of ophthalmic artery between primary open angle glaucoma and normal tension glaucoma. Br J Ophthalmol. 1995;79;732–734.

    Article  PubMed  CAS  Google Scholar 

  21. Findl O, Rainer G, Dallinger S, et al. Assessment of optic disk blood flow in patients with open-angle glaucoma. Am J Ophthalmol. 2000;130:589–596.

    Article  PubMed  CAS  Google Scholar 

  22. Grunwald JE, Piltz J, Hariprasad SM, et al. Optic nerve and choroidal circulation in glaucoma. Invest Ophthalmol Vis Sci. 1998:39;2329-2336.

    Google Scholar 

  23. Izumi N, Nagaoka T, Sato E, et al. Short-term effects of topical tafluprost on retinal blood flow in cats. J Ocul Pharmacol Ther. 2008;24:21–526.

    Article  Google Scholar 

  24. Akaishi T, Kutrashima H, Odani-Kaeabata N, et al. Effects of repeated administration of tafluprost, latanoprost, and travoprost on optic nerve blood flow in conscious normal rabbits. J Ocul Pharmacol Ther. 2010;26:181–186.

    Article  PubMed  CAS  Google Scholar 

  25. Dong Y, Watabe H, Su G, et al. Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries. Exp Eye Res. 2008;87:251–256.

    Article  PubMed  CAS  Google Scholar 

  26. Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T. Effects of prostaglandin PGF2 analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res. 2010;91:853–859.

    Article  PubMed  CAS  Google Scholar 

  27. Mayama C, Ishii K, Saeki T, et al. Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma. Invest Ophthamol Vis Sci. 2010;51:4117–4124.

    Article  Google Scholar 

  28. Kanamori A, Naka M, Fukuda M, et al. Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol. 2009;247:1353–1360.

    Article  PubMed  Google Scholar 

  29. Bull ND, Johnson TV, Welsapar G, et al. Use of an adult retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Invest Ophthalmol Vis Sci. 2011;52:3309–3320.

    Article  PubMed  CAS  Google Scholar 

  30. Burstein NL. Preservative alteration of corneal permeability in humans and rabbits. Invest Ophthalmol Vis Sci. 1984;25:1453–1457.

    PubMed  CAS  Google Scholar 

  31. Majumdar S, Hippalgaonkar K, Repka MA. Effect of chilosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm. 2008;348:175–178.

    Article  PubMed  CAS  Google Scholar 

  32. Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res. 2009;41:118–122.

    Article  PubMed  Google Scholar 

  33. Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33:303–312.

    Article  PubMed  CAS  Google Scholar 

  34. Liang H, Baudouin C, Pauly A, et al. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol. 2008;92:1275–1282.

    Article  PubMed  CAS  Google Scholar 

  35. Traverso CE, Ropo A, Papadia M, et al. A Phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26:97–104.

    Article  PubMed  CAS  Google Scholar 

  36. Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked Phase III study. Acta Ophthalmol. 2010;88:12–19.

    Article  PubMed  CAS  Google Scholar 

  37. Schnober D, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010;8:1459–1463.

    Article  Google Scholar 

  38. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–336.

    PubMed  CAS  Google Scholar 

  39. Hommer A, Mohammed RO, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26:1905–1913.

    Article  PubMed  CAS  Google Scholar 

  40. Erb C, Lanzl I, Seidova SF, Kimmich F. Preservativefree tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Avd Ther. 2011;28:575–585.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmology Department, University of Colorado School of Medicine, 1675 Aurora Court, Aurora, CO, 80045, USA

    Mina B. Pantcheva, Leonard K. Seibold & Malik Y. Kahook

  2. Rose Family Medicine, 4545 East 9th Suite#010, Denver, CO, 80220, USA

    Nida S. Awadallah

Authors
  1. Mina B. Pantcheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonard K. Seibold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nida S. Awadallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Malik Y. Kahook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malik Y. Kahook.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pantcheva, M.B., Seibold, L.K., Awadallah, N.S. et al. Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Therapy 28, 707–715 (2011). https://doi.org/10.1007/s12325-011-0055-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0055-8

Keywords

Search

Navigation